These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 29558810)

  • 1. Bioconjugate Materials in Vaccines and Immunotherapies.
    Jewell CM; Caruso F
    Bioconjug Chem; 2018 Mar; 29(3):571. PubMed ID: 29558810
    [No Abstract]   [Full Text] [Related]  

  • 2. Toll-like Receptor Agonist Conjugation: A Chemical Perspective.
    Ignacio BJ; Albin TJ; Esser-Kahn AP; Verdoes M
    Bioconjug Chem; 2018 Mar; 29(3):587-603. PubMed ID: 29378134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioconjugation Approaches to Producing Subunit Vaccines Composed of Protein or Peptide Antigens and Covalently Attached Toll-Like Receptor Ligands.
    Xu Z; Moyle PM
    Bioconjug Chem; 2018 Mar; 29(3):572-586. PubMed ID: 28891637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic glycopeptides for the development of cancer vaccines.
    Liakatos A; Kunz H
    Curr Opin Mol Ther; 2007 Feb; 9(1):35-44. PubMed ID: 17330400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel vaccines and adjuvants for allergen-specific immunotherapy.
    Crameri R; Rhyner C
    Curr Opin Immunol; 2006 Dec; 18(6):761-8. PubMed ID: 17010585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rekindling cancer vaccines.
    Branca MA
    Nat Biotechnol; 2016 Oct; 34(10):1019-1024. PubMed ID: 27727216
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists.
    Kanzler H; Barrat FJ; Hessel EM; Coffman RL
    Nat Med; 2007 May; 13(5):552-9. PubMed ID: 17479101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of adjuvants for immunotherapy.
    Circelli L; Tornesello M; Buonaguro FM; Buonaguro L
    Hum Vaccin Immunother; 2017 Aug; 13(8):1774-1777. PubMed ID: 28604160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbohydrate-based synthetic vaccines: does the synthesis of longer chains of carbohydrates make this a step ever closer?
    Chu KC; Wu CY
    Future Med Chem; 2012 Sep; 4(14):1767-70. PubMed ID: 23043471
    [No Abstract]   [Full Text] [Related]  

  • 10. Exploring synthetic immunity: From boutique to global.
    Levine BL
    Hum Vaccin Immunother; 2017 Oct; 13(10):2204-2206. PubMed ID: 28945504
    [No Abstract]   [Full Text] [Related]  

  • 11. Harnessing self-assembly to enable modular vaccine design.
    Biotechnol Bioeng; 2017 Feb; 114(2):244. PubMed ID: 28005281
    [No Abstract]   [Full Text] [Related]  

  • 12. Synthetic peptide vaccines: the quest to develop peptide vaccines for influenza, HIV and Alzheimer's disease.
    Bianchi E; Ingallinella P; Finotto M; Joyce J; Liang X; Miller MD; Kinney GG; Ciliberto G; Shiver JW; Pessi A
    Adv Exp Med Biol; 2009; 611():121-3. PubMed ID: 19400121
    [No Abstract]   [Full Text] [Related]  

  • 13. Recent Advances in Toll Like Receptor-Targeting Glycoconjugate Vaccines.
    Li Q; Guo Z
    Molecules; 2018 Jun; 23(7):. PubMed ID: 29966261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic Nanoparticles for Vaccines and Immunotherapy.
    Irvine DJ; Hanson MC; Rakhra K; Tokatlian T
    Chem Rev; 2015 Oct; 115(19):11109-46. PubMed ID: 26154342
    [No Abstract]   [Full Text] [Related]  

  • 15. Dendritic cell immunotherapy for the treatment of neoplastic disease.
    Decker WK; Xing D; Shpall EJ
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):113-25. PubMed ID: 16443510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens.
    Rosenberg SA
    Annu Rev Med; 1996; 47():481-91. PubMed ID: 8712798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmacytoid dendritic cells, a role in neoplastic prevention and progression.
    Lombardi VC; Khaiboullina SF; Rizvanov AA
    Eur J Clin Invest; 2015 Jan; 45 Suppl 1():1-8. PubMed ID: 25524580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide.
    Thompson P; Lakshminarayanan V; Supekar NT; Bradley JM; Cohen PA; Wolfert MA; Gendler SJ; Boons GJ
    Chem Commun (Camb); 2015 Jun; 51(50):10214-7. PubMed ID: 26022217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New directions in the chemistry and biology of carbohydrates.
    Giuliano RM
    Curr Top Med Chem; 2008; 8(2):63. PubMed ID: 18289077
    [No Abstract]   [Full Text] [Related]  

  • 20. The development of synthetic antitumour vaccines from mucin glycopeptide antigens.
    Gaidzik N; Westerlind U; Kunz H
    Chem Soc Rev; 2013 May; 42(10):4421-42. PubMed ID: 23440054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.